Compounds > naproxen
Page last updated: 2024-09-04

naproxen and butylhydroxybutylnitrosamine

naproxen has been researched along with butylhydroxybutylnitrosamine in 3 studies

Compound Research Comparison

Studies
(naproxen)		Trials
(naproxen)		Recent Studies (post-2010)
(naproxen)		Studies
(butylhydroxybutylnitrosamine)		Trials
(butylhydroxybutylnitrosamine)		Recent Studies (post-2010) (butylhydroxybutylnitrosamine)
4,5511,0571,429557180

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's1 (33.33)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Boring, D; Grubbs, CJ; Juliana, MM; Kopelovich, L; Lubet, RA; Patlolla, J; Rao, CV; Steele, VE; Zhang, Y1
Bode, A; Boring, DL; Grubbs, CJ; Juliana, MM; Lubet, RA; Minasian, L; Scheiman, JM; Steele, VE; White, J1
Grubbs, CJ; Juliana, MM; Lubet, RA; Miller, MS; Moeinpour, FL; Mohammed, A; Sei, S; Shoemaker, RH; Suen, CS1

Other Studies

3 other study(ies) available for naproxen and butylhydroxybutylnitrosamine

ArticleYear
Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancers.
    Cancer prevention research (Philadelphia, Pa.), 2009, Volume: 2, Issue:11

    Topics: Alkylating Agents; Animals; Anti-Inflammatory Agents, Non-Steroidal; Azoxymethane; Butylhydroxybutylnitrosamine; Carcinogens; Colonic Neoplasms; Diet; Female; Male; Mammary Neoplasms, Experimental; Methylnitrosourea; Naproxen; Nitric Oxide Donors; Precancerous Conditions; Rats; Rats, Inbred F344; Rats, Sprague-Dawley; Urinary Bladder Neoplasms

2009
Prevention of chemically induced urinary bladder cancers by naproxen: protocols to reduce gastric toxicity in humans do not alter preventive efficacy.
    Cancer prevention research (Philadelphia, Pa.), 2015, Volume: 8, Issue:4

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blotting, Western; Butylhydroxybutylnitrosamine; Carcinogens; Female; Fluorescent Antibody Technique; Humans; Mice; Naproxen; Rats; Rats, Inbred F344; Stomach; Urinary Bladder Neoplasms

2015
Combination of Erlotinib and Naproxen Employing Pulsatile or Intermittent Dosing Profoundly Inhibits Urinary Bladder Cancers.
    Cancer prevention research (Philadelphia, Pa.), 2020, Volume: 13, Issue:3

    Topics: Animals; Anticarcinogenic Agents; Butylhydroxybutylnitrosamine; Carcinogens; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Naproxen; Neoplasm Recurrence, Local; Neoplasms, Experimental; Pulse Therapy, Drug; Rats; Time Factors; Time-to-Treatment; Urinary Bladder; Urinary Bladder Neoplasms

2020